Abstract

In recent years, studies have brought to light preclinical evidence of the ability of cannabinoids to reduce tumor growth in animal models, and clinical trials have been designed to study this activity in patients with glioblastoma. The data in animal models show promising results. So far it has been seen that the administration of THC is safe, and can be carried out without psychoactive effects. These molecules act through receptors coupled to the G protein, which are part of the endocannabinoid system and which have been called CB1 and CB2. THC can attenuate tumor progression in some patients, and appears to have a positive effect on survival, similar to that generated by other chemotherapeutic agents. More trials are needed to validate this antitumor action, both in combination with other therapies, and independently. At this time there is not enough scientific evidence to be able to conclusively affirm that cannabinoid treatment can contribute improve current therapies given to patients with brain tumors or other types of tumors.

Keywords: Glioblastoma; Endocannabinoid System; Antitumor Therapy

References

1. Montero-Oleas N., et al. “Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews”. BMC Complementary Medicine and Therapies1 (2020): 12.
2. Laezza C., et al. “The endocannabinoid system: A target for cancer treatment”. International Journal of Molecular Sciences3 (2020): 747.
3. Turgeman I and Bar-Sela G. “Cannabis for cancer–illusion or the tip of an iceberg: A review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology”. Expert Opinion on Investigational Drugs3 (2019): 285-296.
4. Luís Â., et al. “The effects of cannabinoids on glioblastoma growth: A systematic review with meta-analysis of animal model studies”. European Journal of Pharmacology 4 (2020): 173055.
5. Silver RJ. “The endocannabinoid system of animals”. Animals9 (2018): 686.
6. Śledziński P., et al. “The current state and future perspectives of cannabinoids in cancer biology”. Cancer Medicine3 (2018): 765-775.
7. Hinz B and Ramer R. “Anti‐tumour actions of cannabinoids”. British Journal of Pharmacology10 (2019): 1384-1394.
8. Torres-Román AL., et al. “Oleamide Induces Cell Death in Glioblastoma RG2 Cells by a Cannabinoid Receptor–Independent Mechanism”. Neurotoxicity Research 15 (2020): 1-6.
9. Guzman M., et al. “A pilot clinical study of Δ 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme”. British Journal of Cancer2 (2006): 197-203.
10. Colella B., et al. “EMT regulation by autophagy: a new perspective in glioblastoma biology”. Cancers 3 (2019): 312.
11. Sordillo LA., et al. “Sphingosine kinase inhibitors as maintenance therapy of glioblastoma after ceramide-induced response”. Anticancer Research5 (2016): 2085-2095.
12. Ellert-Miklaszewska A., et al. “Cannabinoid signaling in glioma cells”. InGlioma Signaling (2013): 209-220.
13. Lorente M., et al. “Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action”. Cell Death and Differentiation6 (2011): 959-973.
14. Velasco G., et al. “Anticancer mechanisms of cannabinoids”. Current Oncology 23 (2016): S23.
15. Russo EB. “Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects”. British Journal of Pharmacology7 (2011): 1344-1364.
16. Pertwee RG. “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin”. British Journal of Pharmacology2 (2008): 199-215.
17. Devinsky O., et al. “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. Epilepsia6 (2014): 791-802.
18. Iuvone T., et al. “Cannabidiol: a promising drug for neurodegenerative disorders?”. CNS Neuroscience and Therapeutics1 (2009): 65-75.
19. Rodrigues RS., et al. “Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology”. Molecules7 (2019): 1350.
20. Billakota S., et al. “Cannabinoid therapy in epilepsy”. Current Opinion in Neurology2 (2019): 220-226.
21. Colizzi M and Bhattacharyya S. “Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition”. Current Addiction Reports2 (2017): 62-74.
22. Hinz B and Ramer R. “Anti‐tumour actions of cannabinoids”. British Journal of Pharmacology10 (2019): 1384-1394.
23. Gustafsson SB., et al. “Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil”. Cancer Chemotherapy and Pharmacology4 (2009): 691-701.
24. de la Ossa DH., et al. “Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme”. PLoS One1 (2013): e54795.
25. Yan Y., et al. “Targeting autophagy to sensitive glioma to temozolomide treatment”. Journal of Experimental and Clinical Cancer Research 1 (2016): 23.
26. Esposito G., et al. “The Endocannabinoid System Protects Rat Glioma Cells Against HIV-1 Tat Protein-induced Cytotoxicity MECHANISM AND REGULATION”. Journal of Biological Chemistry52 (2002): 50348-50354.
27. Guzman M., et al. “A pilot clinical study of Δ 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme”. British Journal of Cancer2 (2006): 197-203.
28. GW Pharmaceuticals plc. GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma (2017).
29. López-Valero I., et al. “Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide”. Biochemical Pharmacology 157 (2018): 266-274.
30. López-Valero I., et al. “Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma”. Biochemical Pharmacology 157 (2018): 275-284.

Citation

Citation: Marcos Escosa Bagé. “Cannabinoid Therapy for Glioblastoma Treatment: A Review”. Acta Scientific Neurology 4.2 (2021): 10-16.

Copyright

Copyright: © 2021 Marcos Escosa Bagé. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.